Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Long-Term Outcomes Reinforce the High Efficacy of Biktarvy ® in People with HIV and HBV Coinfection – – Investigational Long-Acting, Twice-Yearly Treatment Regimen of Len ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...

The healthcare sector continues to advance with technological breakthroughs and growing demand for medical services, creating ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Gilead Sciences: GILD is a dominant player ... for its treatment and grab a formidable market share. Based in Foster City, CA, its efforts to bolster its oncology and virology franchises through ...

Gilead Sciences has won Food and Drug Administration ... the virus that causes AIDS. The Foster City, Calif., biopharmaceutical company has previously said it is planning for a potential launch ...

Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV). The company’s broad portfolio includes drugs for liver ...

Gilead Sciences (GILD.O) is a global biopharmaceutical company headquartered in Foster City, California. Founded in 1987, Gilead is recognized for its groundbreaking work in the development of ...